YOUR SEARCH FOR Text 42 RESULTS
11 of Total
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates | Incyte
… in the fourth quarter. Results from the Phase 1 trial evaluating INCA033989, an investigational … In October, results from the Phase 1 trial evaluating INCA33890 (TGFBR2xPD-1 …
12 of Total
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… development programs, including combination trials of ruxolitinib with parsaclisib, … (cGVHD): AGAVE-201, a global pivotal Phase 2 trial of axatilimab in patients with cGVHD is …
13 of Total
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advance
… on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC … on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with …
14 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… in the first half of 2026. A Phase 2 trial evaluating axatilimab (Niktimvo) in … diagnosed chronic GVHD is ongoing. A Phase 3 trial evaluating axatilimab in combination with …
15 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… year. Initial data from the ongoing combination trials of ruxolitinib with INCB57643 (BET) and … (SCAC): Phase 3 (POD1UM‑303) MSI-high endometrial cancer: Phase 2 (POD1UM‑101, POD1UM‑204) …
16 of Total
An Inclusive Environment | Incyte.com
… Inclusion < > < > Incyte Inclusion in Clinical Trials Representing diverse communities within our clinical trials is essential for understanding and …
17 of Total
Incyte Reports Fourth Quarter and Full Year 2025 Financial Results | Incyte
… we expect to have fourteen pivotal clinical trials underway. Incyte enters 2026 with strong … results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab and lenalidomide in …
18 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Symposium, the Phase 3 POD1UM-303/InterAACT2 trial for retifanlimab met the primary endpoint … in patients with ovarian cancer and endometrial cancer whose tumors overexpress Cyclin E1. …
19 of Total
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a
… at 7:30 AM EST PDF Version - Phase 3 frontMIND trial evaluating the efficacy and safety of … results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of …
20 of Total
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalido
… approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, … about the study, please visit https://clinicaltrials.gov/study/NCT04680052 . About Minjuvi ® …